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T-Cell Receptor Gene Therapy: Critical Parameters
for Clinical Success
Carsten Linnemann1, Ton N.M. Schumacher1 and Gavin M. Bendle1
T-cell receptor (TCR) gene therapy aims to induce immune reactivity against tumors by introducing genes
encoding a tumor-reactive TCR into patient T cells. This approach has been extensively tested in preclinical
mouse models, and initial clinical trials have demonstrated the feasibility and potential of TCR gene therapy as a
cancer treatment. However, data obtained from preclinical and clinical studies suggest that both the therapeutic
efficacy and the safety of TCR gene therapy can be and needs to be further enhanced. This review highlights
those strategies that can be followed to develop TCR gene therapy into a clinically relevant treatment option for
cancer patients.
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INTRODUCTION
Over the past few decades, great efforts
have been made to enhance endogen-
ous T-cell reactivity against human
tumors, and in recent years, two
approaches have started to show a
significant clinical effect. First, non-
antigen-specific immunomodulation in
the form of the administration of mono-
clonal antibodies that block cytotoxic
T-lymphocyte antigen-4 or other T-cell
checkpoint molecules have successfully
been used in patients with metastatic
melanoma and renal cell carcinoma
(Brahmer et al., 2010; Hodi et al.,
2010). Second, administration of auto-
logous tumor-infiltrating lymphocytes
(TILs) that have been expanded ex vivo
has been used to treat patients with
metastatic melanoma.When TIL therapy
was administered in combination with
non-myeloablative lymphodepletion, an
impressive 50% objective response rate
was observed in clinical trials at two
different centers (Dudley et al., 2002,
2008, 2010; Besser et al., 2010).
Although these studies demonstrate
the potential value of T cell-based
immunotherapies, there are a number
of limitations associated with these
approaches. First, the success of these
therapies is—at least thus far—re-
stricted to melanoma and renal cell
carcinoma, two tumor types that are
generally assumed to be more immu-
nogenic than other tumors (although
we note that the molecular basis for
such a difference in immunogenicity is
at present unclear). Thus, it is possible
that the tumor-reactive T-cell repertoire
for other human tumors is too small to
mobilize by T-cell checkpoint block-
ade or TIL therapy (Rosenberg et al.,
2008). Second, immunity induced by
these therapies is not specifically
steered toward defined tumor-asso-
ciated antigens (TAAs), and it is plau-
sible that T-cell therapies could
be more effective and/or less toxic if
the immune response was specifically
directed toward defined TAAs.
In contrast to these two approaches
that aim to enhance an undefined
tumor-specific T-cell response, T-cell
receptor (TCR) gene therapy does not
rely on the pre-existing presence of
tumor-reactive T cells, and does allow
one to target defined TAAs of choice.
This approach is based on the observa-
tion that antigen specificities can be
transferred between T cells by introdu-
cing genes encoding the TCRa- and
b-chain that together form the ab-TCR
heterodimer (Dembic et al., 1986).
Thus, introduction of genes encoding
a tumor-reactive TCR can be used to re-
direct patient-derived T cells toward an
antigen of interest, thereby establishing
a tumor-reactive T-cell compartment
that would be otherwise absent.
The concept of genetic engineering
of T-cell immunity has developed from
a somewhat futuristic plan into a
realistic clinical possibility over the last
15 years (Figure 1). Initial studies in the
late 1990s showing that human T cells
could be redirected toward antigen-
expressing cells by TCR gene transfer
(Clay et al., 1999; Cooper et al., 2000)
were followed by work that showed
that both CD4þ and CD8þ T cells
transduced with TCR can function
in vivo in mouse models (Kessels
et al., 2001, 2006; Tahara et al.,
2003; Chamoto et al., 2004; Morris
et al., 2005). Furthermore, subsequent
studies in mice (de Witte et al., 2006,
2008a) demonstrated that the central
underlying rationale for TCR gene
therapy is valid; it is possible to create
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a defined tumor-reactive T-cell com-
partment toward antigens of choice,
irrespective of self-tolerance. In the
above preclinical studies and in the
clinical studies carried out thus far,
g-retroviral vectors were used to transfer
TCR genes into T cells. This approach
leads to the long-term redirection of
T-cell specificity as transferred TCR
genes are stably integrated in the
genome of redirected T cells. Recently,
lentiviral vectors have also been
used in a number of preclinical studies
(Yang et al., 2008, 2010; Bobisse et al.,
2009; Perro et al., 2010), and a proof-
of-principle study has shown that a
non-viral transposase-mediated gene
transfer system can also be used to
achieve stable transfer of TCR genes in
T cells (Peng et al., 2009).
Two phase I clinical trials involving
TCR gene therapy have been performed
in melanoma patients thus far, both by
the group of Rosenberg at the National
Cancer Institute surgery branch (Mor-
gan et al., 2006; Johnson et al., 2009).
In the first trial, patients with metastatic
melanoma were treated with autolo-
gous T cells modified with a TCR
(termed ‘‘DMF4’’) specific for the mel-
anocyte differentiation antigen MART-
1, and gene-modified cells were in-
fused after a lymphodepleting regimen
(Morgan et al., 2006). Although no
treatment-related toxicity was ob-
served, the objective response rate of
17% (2 out of 17 patients) was low
compared with that observed in TIL
therapy trials performed by the same
group (Dudley et al., 2002, 2008,
2010). This discrepancy may at least
in part be related to the low level of
TCR expression on gene-modified T
cells, as well as to the poor persistence
of TCR-modified T cells after infusion
in this study.
In the second clinical trial, patients
with metastatic melanoma were treated
with T cells modified with either a
MART-1-specific TCR (DMF5) that ex-
hibits a higher affinity than the pre-
viously used DMF4 TCR or a TCR (154)
specific for the melanocyte differentia-
tion antigen gp100 (Johnson et al.,
2009). The expression of the intro-
duced TCR and the persistence of
modified T cells were markedly in-
creased compared with the first trial,
which may have been a result of the
intrinsic properties of TCRs (Sommer-
meyer et al., 2006; Heemskerk et al.,
2007) and the format of the gene
expression cassette used in this second
clinical trial (internal ribosome entry
site vs P2A). Despite this, objective
clinical response rates remained rela-
tively low, with 30% (6/20 patients) for
the DMF5 TCR and 19% (3/16 patients)
for the gp100 (154) TCR. Thus, the
clinical experience with TCR gene
therapy in these studies can be sum-
marized as follows: although there is
now clear evidence for the clinical
feasibility of TCR gene therapy, there is
only limited proof for efficacy, and this
issue needs to be addressed.
During the time in which these
clinical trials were performed, a num-
ber of preclinical studies were carried
out, which provide leads for the devel-
opment of more effective TCR gene
therapy protocols. In addition, precli-
nical work has also revealed some
potential toxicities of TCR gene therapy
that need to be addressed. Here, we
combine data obtained from the pre-
clinical and clinical studies over the
past years to discuss how further
development of TCR gene therapy
may take place, focusing on three main
questions:
1. What tumor antigens represent
effective and safe targets for TCR
gene therapy and how can suitable
TCRs that target these antigens be
generated?
2. Which of the potential toxicities
associated with TCR gene therapy
represent ‘‘real’’ risks, and what
strategies can best be used to
prevent or control such toxicities?
3. Which ‘‘adjuvant strategies’’ can
best be used to enhance the
clinical efficacy of TCR gene ther-
apy of cancer?
CHOICE OF SUITABLE TARGET
ANTIGENS AND ISOLATION OF PO-
TENT TCRS FOR TCR GENE THERAPY
Which antigens to pick? General con-
siderations with regard to efficacy
Conceptually, there are a number of
criteria that can be used to judge the
potential suitability of a tumor antigen
as a target for TCR gene therapy. With
regard to safety, a high degree of
tumor-specific expression is desirable
to limit the chances of damage to
normal tissues, and this important issue
is discussed in greater detail below. In
terms of efficacy, the following factors
need to be taken into consideration.
First, the heterogeneity of expression of
the target antigen within the population
1999
2001
2006
2009
2010
1986
First report that human PBLs
can be redirected with the
introduction of TCR genes to 
display tumor reactivity in vitro
(Clay et al., 1999).
Mouse study proving that
TCR gene therapy can break
immunological tolerance
towards a self-tumor antigen
(de Witte et al., 2006). 
First clinical trial with
TCR-modified T-cells to 
treat patients with metastatic
melanoma at the NIH, USA
(Morgan et al., 2006). 
Second clinical trial with
TCR gene therapy treating
patients with metastatic
melanoma at the NIH, USA
(Johnson et al., 2009)
Demonstration that
T-cell specificity is
solely determined by
the TCRαβ genes 
(Dembic et al., 1986). 
Development of transgenic mice
expressing a diverse human TCR
repertoire that may be a valuable
source of TCRs for TCR gene 
therapy (Ping et al., 2010).
First study showing that
TCR-modified T-cells are functional 
in vivo and can mount an immune
response upon antigen encounter
(Kessels et al., 2001).
Figure 1. Milestones in the development of TCR gene therapy. NIH, National Institutes of Health; PBLs, peripheral blood lymphocytes; TCR, T-cell receptor.
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of cancer cells is likely to influence
therapeutic efficacy. For example, tu-
mor-initiating cancer stem cells have
been identified in a number of different
cancers (Li et al., 2007; O’Brien et al.,
2007; Maitland and Collins, 2008;
Schatton et al., 2008), and if expression
of the target antigen is not found on
these cells, treatment is unlikely to be
successful unless cancer stem cells
would be eradicated through bystander
killing. A second factor expected to
influence therapeutic efficacy is the
likelihood of downregulation of target
antigen expression. The risk of tumor
escape by downregulation of target
antigen expression may potentially be
minimized by targeting proteins that
have an essential role in maintaining
the malignant phenotype. However,
the number of antigens that fulfills this
criterion—and is still sufficiently tumor
specific (see below)—is likely to be
low. A third factor that is likely to
influence therapeutic efficacy relates to
the expression profile of the target
antigen in normal tissues, as efficacy
may be compromised by dose-limiting
toxicity as a result of the destruction on
normal tissues expressing the target
antigen (Parkhurst et al., 2011).
Which antigens to pick: safety concerns
Tumor-associated antigens can be sub-
divided into discrete categories based
on their expression patterns in normal
tissues and on whether these antigens
are genetically ‘‘self’’ or arise as a
consequence of mutations.
Cancer/testis (C/T) antigens are ex-
pressed in various human cancers, and
also in the human germ line (van der
Bruggen et al., 1991; Jager et al., 1998;
Simpson et al., 2005). Expression of
C/T antigens in other healthy tissues
is generally presumed to be absent
(Rimoldi et al., 1999; Caballero and
Chen, 2009; Schultz-Thater et al.,
2011), which marks them as the class
of shared TAAs with the most restricted
expression pattern in untransformed
cells. There is evidence though that at
least certain C/T antigens can be
expressed by thymic epithelial cells,
suggesting that there may be some level
of T-cell tolerance toward these anti-
gens. A second class of shared TAAs is
formed by tissue-specific differentiation
antigens, a group of antigens that is
typically only expressed by the tumor
and its tissue of origin. Examples
of tissue-specific differentiation anti-
gens include the MART-1/Melan-A
(Kawakami et al., 1994a) and gp100
(Kawakami et al., 1994b) antigens that
are expressed in both melanocytes and
melanoma cells, and which were tar-
geted in the first two clinical trials of
TCR gene therapy (Morgan et al., 2006;
Johnson et al., 2009). Tissue-specific
differentiation antigens have also been
described for cell lineages in other
organs, such as the prostate (Cunha
et al., 2006). It is noted though that—in
spite of their name—these lineage
differentiation antigens are often also
expressed to some extent in other
(developmentally related) cell types
(Johnson et al., 2009), a potential cause
of on-target toxicity that will be
discussed further below. A third class
of TAAs consists of proteins, which are
not only frequently expressed at
elevated levels in tumors but are also
present in lower levels in various
normal tissues. Examples of this class
of TAAs include p53 (Vierboom et al.,
1997), Her2/neu (Disis et al., 1994),
MDM2 (Stanislawski et al., 2001;
Bendle et al., 2004), and cyclin-D1
(Sadovnikova et al., 1998).
A final class of TAAs is formed by
mutated self-proteins that can poten-
tially form targets for T cell-based
immunotherapy of cancer (Wolfel
et al., 1995; Carbone et al., 2005;
Lennerz et al., 2005; Graf et al., 2007).
When the mutation involved first oc-
curred within the cancer-initiating cell
(or one of its daughters), this class of
tumor antigens represented the safest
possible target for TCR gene therapy,
with a maximal degree of tumor
specificity. It is important to realize
though that certain driver mutations in
cancer development are hereditary. As
an example, the CDK4 mutation that
results in a novel HLA-A2-restricted
T-cell epitope (Wolfel et al., 1995) may
seem a perfect target for TCR gene
therapy but is sometimes observed in
familial melanoma (Lang et al., 2011).
For these patients, the targeting of this
antigen would certainly not result in
selective tumor cell recognition.
Nevertheless, the majority of mutations
within each tumor genome are likely to
be tumor specific, and can therefore be
considered potential major histocom-
patibility complex (MHC) class I-re-
stricted neo-antigens.
Although some of the neo-antigens
that are formed by mutations can be
shared by patients (something further
discussed below), the majority of these
neo-antigens is likely to be patient
specific. It is currently unknown to
what extent recognition of such pa-
tient-specific neo-antigens contributes
to clinical responses upon TIL therapy
or anti-CTLA4 treatment, and this will
be an important issue to address. In
particular, if recognition of patient-
specific neo-antigens would turn out
to be predominantly responsible for
observed clinical responses, this would
represent a significant setback for the
TCR gene therapy field, as the targeting
of patient-specific antigens by TCR
gene therapy is clearly a much more
demanding task than that of shared
antigens.
A prevailing view among tumor
immunologists has been that, despite
a lack of tumor-specific expression,
even TAAs that are widely expressed
in normal tissues (such as p53, MDM2.
Her2/neu) may represent safe targets
for T cell-based immunotherapeutic
approaches. This view has been based
on the fact that for many of these TAAs,
expression is increased in tumor cells
relative to normal cells and this could
provide a ‘‘window of opportunity’’,
allowing tumor cell destruction without
destruction of normal cells. The lack of
toxicity observed in clinical trials of
cancer vaccines that aim to induce
T-cell responses against antigens such
as p53 and CEA has sometimes been
taken as evidence for the safety of
targeting these antigens in adoptive
T-cell therapy trials. However, this
reasoning is flawed: vaccination
against TAAs aims to mobilize an
endogenous T-cell response that for
most self-antigens will be small in size
and quality/affinity as a result of
immunological tolerance (Theobald
et al., 1997; Romieu et al., 1998;
Bendle et al., 2007; Bos et al., 2008;
de Witte et al., 2008a). In contrast, TCR
gene transfer can be used to break
tolerance and induce robust responses
1808 Journal of Investigative Dermatology (2011), Volume 131
C Linnemann et al.
TCR Gene Therapy
to TAAs, using TCRs that are as potent
as any anti-viral TCR. Therefore, the
fact that a TAA has been shown a safe
target in vaccination studies is not
informative with respect to its use as a
target for TCR gene therapy.
Strong experimental support for this
notion comes from a number of recent
studies that have demonstrated that the
introduction of a high-avidity T-cell
repertoire can result in the destruction
of normal tissues that express this target
antigen. For example, although the
targeting of p53 by vaccination in both
preclinical and clinical studies has not
resulted in any significant toxicities
(Offringa, 2009), it has been demon-
strated that mice that are treated with T
cells transduced with a high-affinity
p53-specific TCR die as a result of
destruction of the hematopoietic com-
partment, a toxicity that is dependent
on p53 expression by the hematopoie-
tic compartment (Lauwen et al., manu-
script submitted). The potential danger
of targeting p53 by TCR gene therapy
has been underscored by an in vitro
study in which human T cells trans-
duced with a high-affinity p53-specific
TCR were observed to recognize some
normal cells expressing p53 (Theoret
et al., 2008). Notably, in the experi-
ments conducted by Offringa and
colleagues, toxicity was only observed
when the T-cell populations used for
TCR gene modification were unable to
present the p53 epitope themselves. In
cases in which T cells also do express
the antigen that is being targeted,
fratricide of these cells is likely to
explain the absence of pathology upon
cell administration. Although such fra-
tricide prevents ablation of the host
hematopoietic system, it will obviously
also compromise the anti-tumor effect
of these cells.
In line with data on the targeting of
p53, the targeting of CEA with a high-
affinity CEA-specific T-cell compart-
ment has been shown to lead to fatal
colitis in mice as a result of CEA
expression on the intestinal tissue (Bos
et al., 2008). Severe colitis was likewise
observed in a recent trial in three out of
three patients who received T cells
modified with a CEA-specific TCR
(Parkhurst et al., 2011), an observation
that underscores the fact that data
obtained in well-chosen mouse models
can be useful to assess safety risks.
Finally, the fact that even a low level of
antigen expression in vital tissues can
form a safety risk is emphasized by two
recent clinical studies that used T cells
transduced with chimeric antigen re-
ceptors. First, Lamers et al. (2006) have
demonstrated that treatment of renal
cell carcinoma patients with T cells
transduced with a chimeric antigen
receptor specific for carbonic anhy-
drase IX leads to liver toxicity. Simi-
larly, Rosenberg et al. have recently
observed severe lung toxicity that
resulted in the death of a patient after
infusion of T cells transduced with a
Her2/neu-specific chimeric antigen re-
ceptor (Morgan et al., 2010). In both
cases, a low level of target antigen
expression was observed in the organ
involved.
Are there cases in which toxicity is,
due to on-target recognition, accepta-
ble? In the second clinical trial of TCR
gene therapy in which the MART-I and
gp100 melanocyte differentiation anti-
gens were targeted with high-affinity
TCRs, a significant number of patients
experienced treatment-induced toxici-
ties that can be explained by the
destruction of normal MART-I/gp100-
expressing cells in the skin, eye, and
ear (Johnson et al., 2009). In this case,
these toxicities could be successfully
treated by the application of topical
steroids and therefore may be viewed
as clinically acceptable. These data
demonstrate that expression by non-
transformed cells can be acceptable,
provided that antigen expression is
restricted to non-essential tissues. To
evaluate whether the toxicity that can
be expected is likely to be acceptable,
a rigorous assessment of the expression
pattern of any new antigen that is
targeted by TCR gene therapy is critical
before the start of clinical trials. This
assessment should at least involve the
analysis of gene expression data in
different human tissues. However, it is
important to realize that gene expres-
sion analyses will likely fail to detect
expression of an antigen in a small
subset of (perhaps critical) cells within
an organ. As an example, toxicity seen
in the trial by Lamers et al. (2006)
would not be predicted by the sole
analysis of microarray data of the
human liver. Owing to this concern,
analysis of protein levels at the cellular
level (i.e., by immunohistochemistry)
clearly seems a preferred approach.
Furthermore, as the most important
question is whether immunologically
relevant levels of the target antigen of
interest are expressed in normal tissues,
it also seems valuable to directly assess
recognition of a large panel of human
cell types by TCR-modified T cells (M
Heemskerk (Leids Universitair Medisch
Centrum) personal communication).
These types of preclinical studies on
antigen expression will provide a cer-
tain degree of confidence about the
safety of targeting a given antigen and
thereby aid in rational antigen choice.
However, for many target antigens,
expression will not be fully tumor
specific, and the safety profile of TCRs
that target such an antigen can only be
definitively determined by clinical test-
ing. Initial clinical studies targeting
such antigens should therefore assess
the consequences of escalating levels
of the TCR-modified T-cell response. If
designed in analogy with safety studies
for other pharmaceuticals, such a phase
I study would involve the infusion of
increasing numbers of TCR-modified T
cells. However, when T-cell adminis-
tration is performed subsequent to
lymphodepletion, this concept of clas-
sical dose escalation becomes proble-
matic, as the administration of a low
TCR-modified T-cell dose will be ac-
companied by an increased ability to
undergo in vivo homeostatic prolifera-
tion. To address this issue, we would
propose to replace dose escalation by
‘‘frequency escalation’’ in such safety
studies, in which a constant number of
T cells is infused of which an increas-
ingly high percentage is modified with
the TCR of interest.
Of the three commonly considered
classes of target antigens for TCR gene
therapy (the differentiation antigens, C/T
antigens, and overexpressed antigens),
C/T antigens probably represent the
most promising targets for TCR
gene therapy of cancer, taking current
technology and data into account.
First, of these three classes of TAA,
C/T antigens represent the safest set
of targets for TCR gene therapy, as
www.jidonline.org 1809
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expression in all normal tissues that can
be accessed by the immune system
seems to be absent (Rimoldi et al.,
1999; Caballero and Chen, 2009;
Schultz-Thater et al., 2011). Second,
for many C/T antigens, expression is
observed in various human cancers
(Simpson et al., 2005), which means
that relatively large groups of patients
can potentially be treated. As a down-
side, although C/T antigens are ex-
pressed in diverse human cancers, the
frequency of expression is often rela-
tively low, making clinical trial enroll-
ment slow. Furthermore, expression of
these antigens is often heterogeneous
(Jungbluth et al., 2000; Simpson et al.,
2005), and we lack data that show
whether the targeting of C/T antigens
with heterogeneous expression can
lead to sustained cancer regression.
Future clinical trials with TCRs specific
for C/T antigens will reveal whether the
current optimism about these antigens
is justified (Zhao et al., 2005; Chinna-
samy et al., 2011).
A class of tumor antigens that is not
commonly considered as targets for
TCR gene therapy is formed by muta-
tions that are shared between patients
and that are sometimes also observed
in different tumors types (Warren and
Holt, 2010). Conceptually, these
shared mutated antigens are very at-
tractive targets for TCR gene therapy for
the following reasons. First, as dis-
cussed above, most of these antigens
are likely to be safe targets owing to
their exclusive expression in tumor
cells. Second, targeting these mutations
should be clinically feasible in terms of
cost, time taken to generate the appro-
priate TCRs, and clinical trial enroll-
ment. Third, the fact that these
mutations are shared suggests that they
may be ‘‘driver mutations’’ that have an
essential role in maintaining the malig-
nant phenotype (Bignell et al., 2010),
and escape of T-cell recognition by
downregulating expression of the mu-
tated antigen is therefore unlikely.
However, it is likely that many of the
mutations that are shared between
individuals are effectively ‘‘invisible’’
to T cells. This is because the combined
probability of a peptide encoding a
mutation (1) being processed by the
HLA class I processing pathway, (2)
being presented by a HLA allele, and
(3) being immunogenic is very small.
Nevertheless, given that these antigens
are conceptually very attractive targets
for TCR gene therapy, it does seem
worthwhile to assess whether any of
these shared mutations encode immu-
nogenic peptide epitopes that are pre-
sented by common HLA alleles.
Although shared mutated antigens
represent a conceptually more attrac-
tive target for TCR gene therapy,
the majority of neo-antigens within
each tumor is likely to be patient
specific. The targeting of such unique
patient-specific mutated antigens
would require patient-specific TCR
gene therapy, an approach that even
5 years ago would have been viewed as
impossible from both a technological
and a financial point of view. However,
the rapid development of next-genera-
tion sequencing technologies (Metzker,
2010) means that routine sequencing of
individual tumor genomes is becoming
a reality, thereby enabling the identifi-
cation of potential neo-antigens on
a per-patient basis. Furthermore,
approaches for the identification and
isolation of antigen-specific T cells
have also gained substantially in
throughput over the past years (Toebes
et al., 2006; Hadrup et al., 2009;
Newell et al., 2009). If the time
required for TCR generation and vali-
dation can also be reduced substan-
tially in the coming years, it does seem
possible that, tailor-made TCR gene
therapy can at some point be tested in
the clinic.
How to get the TCR?
Having decided which antigen to
target, the essential next step is to
obtain a TCR that recognizes this
peptide–MHC complex, preferably with
high affinity. One source of TCRs for
TCR gene therapy that has already been
exploited clinically is patient material.
Both MART-1-specific TCRs used in the
clinic thus far were isolated from a
melanoma patient who experienced
tumor regression after TIL therapy
(Morgan et al., 2006; Johnson et al.,
2009). Although it clearly seems
preferable to isolate TCRs from patients
who experience tumor regression
after therapy than from patients who
progress, it is important to point out
that the mere presence of a given
antigen-specific T-cell population does
not inform us of its role in cancer
regression. If more data were available
on the relationship between specific
T-cell reactivities and clinical course,
such data could perhaps be used to
make a more informed choice of TCRs
for use in gene therapy trials. Toward
this goal, we have recently established
a research line in collaboration with
the NIH Surgery Branch (Bethesda,
MD) and the Chaim Sheba Medical
Center (Tel Aviv, Israel) that aims to
gain insights into the composition
of the shared TAA-reactive T-cell com-
partment in melanoma patients treated
with TIL therapy. Using a high-through-
put MHC tetramer screening platform
(Hadrup et al., 2009) based on some
150 HLA-A2-restricted melanoma-
associated peptides, we have estab-
lished that TIL therapy induces a
demonstrable increase in the tumor-
reactive T-cell compartment (Shu et al.,
manuscript in preparation). Future ex-
periments will aim to establish whether
the presence of certain T-cell reactiv-
ities can perhaps be correlated with
clinical course.
Although patient material will likely
remain a source for TCRs used in TCR
gene therapy, some limitations should
be noted. First, it will not be possible to
obtain TCRs against any given antigen
because of immunological self-toler-
ance. Second, for those TCRs that can
be identified in patient material, their
affinity for cognate peptide may be
suboptimal, again as a result of self-
tolerance. As it has been shown that
high-avidity T cells mediate better
tumor control than their low-avidity
counterparts (Zeh et al., 1999; Cordaro
et al., 2002; Yang et al., 2002), and as
tumors may present low amounts of
antigen or MHC (Purbhoo et al., 2006),
the clinical efficacy of TCRs obtained
from low-avidity T cells may not be
sufficient to mediate cancer regression.
To allow the isolation of TCR genes
without the limitations of self-tolerance,
various technological platforms have
been developed in the past 15
years. These platforms that include
allo-CTL systems (Sadovnikova and
Stauss, 1996; Sadovnikova et al., 1998;
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Leisegang et al., 2010), HLA-transgenic
mice (Stanislawski et al., 2001), and
phage/yeast/T-cell display systems
(Holler et al., 2000; Kessels et al.,
2000; Li et al., 2005) have been
extensively described in a recent re-
view (Uckert and Schumacher, 2009)
and will not be discussed here. How-
ever, a major step toward the straight-
forward generation of TCRs against
human antigens was recently achieved
by the Blankenstein group (Li et al.,
2010). In a heroic effort, this group
created a mouse model in which the
entire human TCR loci were introduced
and their murine counterparts were
inactivated. As these hTCR mice also
express human MHC molecules (HLA-
A2 in the recent paper, but others sure
to come), this mouse model allows one
to generate fully human TCRs against
epitopes of interest. hTCR mice from
Blankenstein display a diverse TCR
repertoire with marked similarities to
the human TCR repertoire. Further-
more, these mice were shown to be
capable of mounting a T-cell response
against a series of different antigens,
suggesting that these mice can form a
very valuable source of TCRs for use in
TCR gene therapy. In addition to its
value for the generation of a collection
of TCRs for clinical use, the model
should also be useful to address funda-
mental questions with regard to T-cell
tolerance against different classes of
TAAs. For instance, is the affinity of
human TCRs specific for human C/T
antigens similar for T cells isolated from
mice and humans, or is there an
imprint of tolerance, even for antigens
with such a restricted tissue expression?
OFF-TARGET SAFETY RISKS OF TCR
GENE THERAPY
In addition to the potential for on-
target toxicity described above, there
are a number of potential off-target
safety risks associated with TCR gene
therapy that have been known for years
(Schumacher, 2002; Bendle et al.,
2009). However, recent studies have
highlighted that one of these risks is
more than just a theoretical concern.
In particular, the pairing of endogenous
and introduced TCR chains in TCR-
modified T cells is known to lead to
the formation of so-called ‘‘mixed TCR
dimers’’ (Figure 2). This repertoire of
newly formed TCRs has obviously not
been screened against self-reactivity,
and it has been argued that the TCR-
modified T-cell pool may therefore be
reactive against undefined self-antigens
(Schumacher, 2002). Only recently,
experimental evidence has been ob-
tained that demonstrates that the self-
reactive T-cell repertoire that is created
upon the formation of mixed TCR
dimers can indeed result in autoim-
mune destruction (Bendle et al., 2010;
van Loenen et al., 2010). In particular,
the Heemskerk group used primary
human T cells to show that mixed
TCR dimers that display auto-reactivity
in in vitro assays are readily formed
on human TCR-modified T cells (van
Loenen et al., 2010). Furthermore, our
work showed the potential in vivo con-
sequences of such de novo generated
self-reactivity, by demonstrating that
mixed TCR dimer formation can lead
to lethal cytokine-driven autoimmune
pathology in mouse models of TCR
gene therapy. It is important to point
out that this pathology, termed ‘‘TCR
gene therapy-induced graft-versus-host
disease,’’ only becomes apparent under
conditions in which the TCR-modified
T-cell response is vigorous. However, it
is observed for 5 out of 5 TCRs tested
and under different in vivo conditions
(Bendle et al., 2010).
If the formation of mixed TCR
dimers can lead to graft-versus-host
disease, one would predict that it
would be valuable to limit the forma-
tion of mixed TCR dimer expression on
TCR-modified T cells. To this end, we
have shown that a combination of two
TCR engineering strategies can be used
to ameliorate the observed mixed TCR
dimer-dependent autoimmunity in
mice. In particular, the use of TCR
engineered with an additional inter-
chain disulphide bond—an approach
first developed by Greenberg and
colleagues (Kuball et al., 2007)—in a
gene expression cassette that uses a
virus-derived P2A element (Uckert and
Schumacher, 2009) to link the TCR-a
and TCR-b genes can limit or prevent
autoimmunity in mice after TCR gene
transfer (Bendle et al., 2010). Impor-
tantly, in addition to enhancing the
safety of TCR gene therapy, this com-
bination of TCR engineering strategies
also enhances the anti-tumor efficacy
of TCR gene therapy in mice (our
unpublished observation).
Although mixed TCR dimer-depen-
dent toxicity has been seen in mice, no
such toxicity has been observed in the
clinical trials of TCR gene therapy
carried out to date (Morgan et al.,
2006; Johnson et al., 2009; Parkhurst
et al., 2011). As a result of this, it has
been argued that TCR gene therapy-
induced graft-versus-host disease is a
problem unique to mice, and that such
toxicity does not form a significant risk
for future clinical trials (Rosenberg,
2010). However, it took almost a
decade of optimizing conditions for
TCR-modified T-cell therapy for mixed
dimer-dependent toxicity to be ob-
served in mouse models, and in early
mouse experiments, it was in fact also
Polyclonal
T-cell pool
TCR gene
transfer
Two mixed-TCR dimers per transduced
T-cell with unpredictable specificity
+
Figure 2. Formation of mixed-TCR dimers upon TCR gene transfer. The introduction of a new
TCR into a T cell can lead to pairing of endogenous and introduced TCR chains. Theoretically,
two new TCRs consisting of one endogenous and one introduced TCR chain can be formed.
Problematically, the specificity of these mixed-TCR dimers cannot be predicted and may lead to
autoreactivity. TCR, T-cell receptor.
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perceived as a non-issue (de Witte
et al., 2006). As increasing the in vivo
function of TCR-modified T cells in
humans is also desirable, and as auto-
reactive mixed TCR dimers are ob-
served in vitro on human TCR-modified
T cells (van Loenen et al., 2010), we
disagree with the viewpoint that mixed
TCR dimer-dependent toxicity cannot
occur in the human situation. Indeed,
there is no conceptual framework that
would explain why mixed dimer-ex-
pressing cells would be toxic to mice
but not to men. Thus, there is a very
strong rationale for using strategies to
limit autoreactive mixed TCR dimer
formation in future clinical trials of TCR
gene therapy, especially as such strate-
gies do not have to reduce TCR-
modified T-cell function.
IDENTIFYING STRATEGIES THAT
ENHANCE THE ANTI-TUMOR
EFFICACY OF TCR GENE THERAPY
Although the toxicity issues described
above are clearly a concern, the
disappointing clinical responses ob-
served to date indicate that the most
important issue at present is to under-
stand what it takes to induce durable
clinical responses by TCR gene ther-
apy. The low response rate in the two
trials by Rosenberg and colleagues may
at least in part be explained by the
nature of the antigens that were tar-
geted: the identified epitopes from
melanocyte differentiation antigens
are those to which T-cell tolerance is
not strict, and this may imply that their
presentation by tumor cells is also
inefficient. In addition, contrary to
T-cell responses in TILs, TCR gene-
modified T-cell responses are mono-
specific, and efficacy may possibly be
enhanced by simply targeting multiple
antigens simultaneously, something
that will undoubtedly be tested in the
near future (Figure 3).
It is also likely though that in
addition to the nature of the target
and the number of targets chosen, the
anti-tumor efficacy of TCR gene ther-
apy can also be increased by other
alterations. Support for this notion is
provided by studies showing that there
are a number of parameters that can be
manipulated to enhance the therapeu-
tic efficacy of TCR-modified T cells in
mice. First, adoptive T-cell transfer
studies have demonstrated that
depletion of the endogenous T-cell
pool of the host with lymphodepleting
chemotherapy or total body irradiation
greatly increases anti-tumor immunity
(Overwijk et al., 2003; Rosenberg
and Dudley, 2004). Second, enhancing
the expression of the introduced TCR
can greatly improve the anti-tumor
efficacy of TCR-modified T cells (de
Witte et al., 2008b). Third, the compo-
sition of the cell graft affects the
anti-tumor potential of TCR-modified
T cells, with a high precursor frequency
of TCR-modified T cells in the cell
graft leading to an enhanced anti-tumor
efficacy even if the absolute number of
TCR-modified T cells that is given is
unchanged (de Witte et al., 2008b).
Although these strategies all enhance
the anti-tumor efficacy of TCR-modi-
fied T cells, the clinical trials of
TCR gene therapy performed to date
already used lymphodepletion, opti-
mized TCR transgene cassettes, and
reached a high frequency of TCR-
modified T cells. Nevertheless, the
number of clinical responses observed
was relatively low. This suggests that
additional parameters may also need to
be manipulated to achieve durable
clinical responses with TCR gene ther-
apy, the most promising of which are
discussed below.
Manipulation of the cytokine milieu
in the form of systemic administration
of IL-2 to patients was used in clinical
trials of TCR gene therapy to support
the survival/expansion of the adop-
tively transferred TCR-modified T cells.
However, it is likely that further refine-
ment of this approach with regard to
both the cytokines used and the way in
which they are provided (systemic vs
local production) will lead to improve-
ments in the therapeutic efficacy of
TCR gene therapy. In terms of which
cytokines are manipulated, data ob-
tained from preclinical models
suggest that supplementation with al-
ternative cytokines to IL-2, such as IL-7
(Pellegrini et al., 2009), IL-12 (Kerkar
Milestone
Treatment of tumors that are not
classical targets for cancer
immunotherapy
Use of combinations of T-cell 
populations modified with
different TCRs
Targeting of tumors with TCR modified
cells that have also been endowed
with other functionalities
(e.g., enhanced cytokine production)
Combining TCR gene therapy 
with administration of monoclonal
antibodies blocking negative
regulators of T-cell activation/function 
(e.g., CTLA4-lpilimumab; PD1-MDX-1106)
Combining TCR gene therapy 
with small-molecule inhibitors
for the treatment of cancer
(e.g., BRAF inhibitor PLX4032)
Potential significance
Clinical assessment of the efficacy
and safety of approaches that aim
to enhance antitumor function
of TCR-modified T-cells 
Clinical assessment of ‘combination therapy’ 
that aims to increase the durability of
clinical responses by reducing
the likelihood of tumor escape
Assessment of the question whether such an
approach can reduce the likelihood of tumor
escape by antigen downregulation
Evidence for the notion that TCR gene therapy
can be used to treat a wide variety of
hematological and solid malignancies
Figure 3. Potential future milestones in the clinical development of TCR gene therapy. TCR, T-cell receptor.
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et al., 2010), IL-15 (Klebanoff et al.,
2004), or IL-21 (Zeng et al., 2005)
may be better able to promote
anti-tumor efficacy of TCR-modified
T cells.
Second, systemic delivery of cyto-
kines is associated with significant side
effects for cytokines such as (high-dose)
IL-2 and IL-12 (Kerkar et al., 2010;
Krieg et al., 2010). To avoid this
toxicity, two different approaches that
enable more localized production of
cytokines have been developed. The
first approach involves the conjugation
of cytokine-loaded nanoparticles to the
surface of T cells before adoptive cell
transfer (Stephan et al., 2010). This
approach is relatively straightforward
and enables localized delivery of not
only cytokines but also a range of other
potentially useful small molecules.
However, the duration of cytokine
supply will ultimately be time limited,
and whether this is a pro or con
remains to be established. The second
approach involves the genetic engi-
neering of TCR-modified T cells, there-
by enabling cells to produce the
cytokine themselves long term (Kerkar
et al., 2010). In this case, it may be
preferable to have cytokine production
regulated in an inducible manner
(either by TCR triggering or by a
pharmacological agent) to limit the
chances of treatment-related toxicities
like those observed with IL-12-engi-
neered TCR-modified T cells (Kerkar
et al., 2010). In addition to localized
production of cytokines, localized in-
hibition of the effect of certain cyto-
kines may also enhance TCR gene
therapy efficacy. For example, tumor-
derived production of TGF-b has
marked suppressive effects on anti-
tumor T-cell responses (Thomas and
Massague, 2005; Wrzesinski et al.,
2007), and blockade of TGF-b signaling
in TCR-modified T cells by engineering
them with a dominant-negative TGF-b
receptor-II (Gorelik and Flavell, 2001)
enhances anti-tumor efficacy in a pre-
clinical spontaneous tumor model (our
unpublished data).
In addition to the manipulation of
the cytokine milieu, manipulation of
the cell population used for gene
transfer may also be used to enhance
therapeutic efficacy. Initial studies in
mice (Gattinoni et al., 2005) and more
recent clinical studies (Zhou et al.,
2005; Scheinberg et al., 2009) have
demonstrated that the acquisition of a
fully differentiated effector phenotype
in T cells before adoptive transfer leads
to diminished in vivo function after
adoptive transfer. In contrast, naive T
cells (Hinrichs et al., 2009), central-
memory T cells (Klebanoff et al., 2005;
Berger et al., 2008), and stem-cell like
memory T cells (Gattinoni et al., 2009)
have been shown to have superior
in vivo function in preclinical models
on a per-cell basis. At present, there is
no evidence that the presence of ‘‘old-
er’’ cells with limited potential for
clonal expansion within cell grafts
containing ‘‘younger’’ cells is detri-
mental. Therefore, the identification of
more optimized in vitro T-cell activa-
tion and growth regimens that produce
enhanced numbers of ‘‘young’’ cells
seems likely to be of greater value than
the development of technology to
purify less-differentiated cells from a
heterogeneous cell population.
Finally, manipulation of some of the
pathways in T cells that act as negative
regulators of T-cell function may prove
to be a key factor in enhancing the
therapeutic efficacy of TCR gene ther-
apy. T-cell checkpoint blockade, for
instance, in the form of CTLA-4 or PD-1
blockade, has been demonstrated to
enhance anti-tumor T-cell responses in
preclinical models (van Elsas et al.,
2001; Blank et al., 2004; Curran et al.,
2010). Furthermore, CTLA-4 blockade
has recently been demonstrated to
enhance overall survival in a phase III
clinical trial in metastatic melanoma
patients (Hodi et al., 2010), showing
that the efficacy of T-cell checkpoint
blockade is not restricted to (sometimes
contrived) mouse model systems.
Which T-cell checkpoint molecules
would form the most interesting candi-
date targets in the context of TCR gene
therapy? The success of CTLA-4 block-
ade seems at least in part due to
enhanced priming of antigen-specific
T-cell responses. However, in the set-
ting of TCR gene therapy, the priming
phase is really not much of an issue as
large numbers of recently activated
TCR-modified T cells are transferred
into a lymphodepleted host. Owing to
this, PD-1 blockade, or blockade of
other molecules that primarily regulate
T-cell activity in the effector phase of
the anti-tumor response, may form a
more attractive approach to enhance
the efficacy of TCR gene therapy. A
note of caution regarding systemic
immune modulation with monoclonal
antibodies is that it may also lead to an
increase in autoimmune side effects
(Hodi et al., 2010). Therefore, the
specific targeting of immune modula-
tion to TCR-modified T cells may prove
a preferable approach to systemic
immune modulation (Borkner et al.,
2010).
CONCLUSIONS
Much progress has been made in the
development of TCR gene therapy in
recent years, a fact highlighted by how
we have progressed from the first
demonstration of the in vivo function
of TCR-modified T cells in mice (Kes-
sels et al., 2001) to the clinical testing
of TCR gene therapy in cancer patients
(Morgan et al., 2006; Johnson et al.,
2009; Parkhurst et al., 2011) in less
than a decade. However, as discussed
in this review, there are a number
of issues that need to be addressed if
TCR gene therapy is to realize its
considerable promise. Two chief issues
among these are to identify which
tumor antigens can be effectively
and safely targeted with TCR gene
therapy, and to move to clinical trials
in which not only T-cell specificity but
also T-cell functionality is manipulated.
The latter may be achieved either
by changing the environment in
which cells reside or through genetic
engineering of the cells themselves
(Figure 3).
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